Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 86Recurrence 18Neoplasms 6Neoplasms, Plasma Cell 3Lymphoma, Non-Hodgkin 3Sarcoma, Kaposi 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2Leukemia, Myeloid, Acute 2Immunoglobulin Light-chain Amyloidosis 2Chromosome 17 deletion 2Burkitt Lymphoma 2Acquired Immunodeficiency Syndrome 2Waldenstrom Macroglobulinemia 1Smoldering Multiple Myeloma 1Proteostasis Deficiencies 1Plasmacytoma 1Plasmablastic Lymphoma 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multi-centric Castleman's Disease 1Malignant Plasma Cell Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myelomonocytic, Chronic 1Hodgkin Disease 1Hematologic Neoplasms 1Epstein-Barr Virus Infections 1

Interventions

Rituximab 45Cyclophosphamide 38ibrutinib 22fludarabine 22acalabrutinib 21venetoclax 20zanubrutinib 17Lenalidomide 17Bendamustine Hydrochloride 17obinutuzumab 16fludarabine phosphate 14Magnetic Resonance Spectroscopy 14Cytarabine 14Specimen Handling 13CT-P10 13pirtobrutinib 12Biopsy 12glofitamab 10Etoposide 10Whole-Body Irradiation 9Vincristine 7Peripheral Blood Stem Cell Transplantation 7Mycophenolic Acid 7Melphalan 7Doxorubicin 7brexucabtagene autoleucel 6Cyclosporine 6orelabrutinib 5Methotrexate 5Immunotherapy, Adoptive 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Mantle-Cell × pomalidomide × 1 year × Clear all
NCT07257510 2025-12-02

Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma

Peking University Third Hospital

Phase NA Recruiting
34 enrolled
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡